8-methyl-7-((1-methylpiperidin-4-yl)oxy)-3-phenyl-2H-chromen-2-one | 1361199-26-9

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 异黄酮类化合物
• 英文名称: 8-methyl-7-((1-methylpiperidin-4-yl)oxy)-3-phenyl-2H-chromen-2-one
• 英文别名: 8-Methyl-7-(1-methylpiperidin-4-yl)oxy-3-phenylchromen-2-one
• CAS: 1361199-26-9
• 化学式: C₂₂H₂₃NO₃
• 分子量: 349.43
• InChiKey: YPQXELFOWHLYLX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  26
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  38.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2,6-二羟基甲苯 在 吡啶 、 甲醇 、 偶氮二甲酸二异丙酯 、 三乙胺 、 三苯基膦 、 三氯氧磷 作用下， 以 四氢呋喃 、 乙腈 为溶剂， 反应 22.0h， 生成 8-methyl-7-((1-methylpiperidin-4-yl)oxy)-3-phenyl-2H-chromen-2-one
  参考文献：
  名称：

  3-Arylcoumarin Derivatives Manifest Anti-proliferative Activity through Hsp90 Inhibition

  摘要：

  The potential therapeutic benefits associated with Hsp90 modulation for the treatment of cancer and neurodegenerative diseases highlight the importance of identifying novel Hsp90 scaffolds. KU-398, a novobiocin analogue, and silybin were recently identified as new Hsp90 inhibitors. Consequently, a library of 3-arylcoumarin derivatives that incorporated the structural features of KU-398 and silybin was designed, synthesized, and evaluated against two breast cancer cell lines. Western blot analysis confirmed that the resulting 3-arylcoumarin hybrids target the Hsp90 protein folding machinery.

  DOI：

  10.1021/ml300018e

文献信息

• Coumarin based Hsp90 inhibitors with urea and ether substituents
  申请人：University of Kansas

  公开号：US10030006B2

  公开（公告）日：2018-07-24

  Compounds of the formulas: wherein: R1-R4, X1, Y1, and A are as defined herein are provided. Pharmaceutical compositions of the compounds are also provided. In some aspects, these compounds are are useful for the treatment of a disease or disorder. In some embodiments, the disease or disorder is a proliferative disease such as cancer.

  提供了以下式子的化合物： 其中：提供了 R1-R4、X1、Y1 和 A 如本文所定义的化合物。还提供了这些化合物的药物组合物。在某些方面，这些化合物可用于治疗疾病或紊乱。在某些实施方案中，疾病或紊乱是增殖性疾病，如癌症。
• COUMARIN BASED HSP90 INHIBITORS WITH UREA AND ETHER SUBSTITUENTS
  申请人：THE UNIVERSITY OF KANSAS

  公开号：US20160289217A1

  公开（公告）日：2016-10-06

  Compounds of the formulas: wherein: R 1 -R 4 , X 1 , Y 1 , and A are as defined herein are provided. Pharmaceutical compositions of the compounds are also provided. In some aspects, these compounds are are useful for the treatment of a disease or disorder. In some embodiments, the disease or disorder is a proliferative disease such as cancer.
• 3-Arylcoumarin Derivatives Manifest Anti-proliferative Activity through Hsp90 Inhibition
  作者：Huiping Zhao、Bin Yan、Laura B. Peterson、Brian S. J. Blagg

  DOI：10.1021/ml300018e

  日期：2012.4.12

  The potential therapeutic benefits associated with Hsp90 modulation for the treatment of cancer and neurodegenerative diseases highlight the importance of identifying novel Hsp90 scaffolds. KU-398, a novobiocin analogue, and silybin were recently identified as new Hsp90 inhibitors. Consequently, a library of 3-arylcoumarin derivatives that incorporated the structural features of KU-398 and silybin was designed, synthesized, and evaluated against two breast cancer cell lines. Western blot analysis confirmed that the resulting 3-arylcoumarin hybrids target the Hsp90 protein folding machinery.